Targeting clonal heterogeneity in treatment-refractory Glioblastoma with novel and empiric immunotherapies

Glioblastoma (GBM) is the most common primary adult brain tumor, characterized by extensive cellular and genetic heterogeneity. Even with surgery, standard chemotherapy, and radiation, tumor recurrence and patient relapse are inevitable with a median survival rate of

Exploring the benefits of the novel CRISPR endonuclease Cpf1 over Cas9 for genomic engineering

A recently developed technology called CRISPR/Cas9 allows scientists to quickly and precisely edit DNA in living cells and is about to revolutionize molecular biology and genetics. The success of CRISPR/Cas9 is based on its ease of use, effectiveness and cost efficiency. Our aim is to explore a variant of this technology, CRISPR/Cpf1, for its application in genomic engineering and potential benefits.

Effects of Pulse Lighting Regimes on Microalgae Growth

Algae are microorganisms present in all aquatic environments with the ability to grow using sunlight as energy source. This ability can be harnessed to produce biomass for various purposes of industrial interests such as biofuel, animal feed, nutrients, etc. This project seeks to improve the productivity of an algal growth facility while reducing energy costs by exploring alternative illumination methods.

iMALDI-based Assays for Protein Activity to Improve Patient Selection for Therapeutic Akt Inhibitors in Cancer Treatment

Detailed profiling with modern analytical technologies has shown that most cancer types are composed of multiple small sub-populations with distinct molecular signatures. Correct identification of the cancer subtype can predict its response to a particular treatment. Genomics has commonly been applied for this purpose, but in some cases, our ability to predict drug response may be enhanced by instead measuring the drug’s direct protein target.

Development of Cell-Based Functional Assays to Accelerate Commercialization and Therapeutic Application of Recombinant Antibodies

Antibodies are used for treatment of many diseases, including cancer. Within the human immune system, antibodies fight invading bacteria and viruses. We have devised a way to make high-quality antibodies in the laboratory and target them to specific disease-related proteins that have been identified by the scientific community and in our lab. Ensuring that these antibodies work in cells the way we intend them to in the body is a critical step of identifying their potential as therapeutic agents and also in the commercialization process.

Developing Vitamin D Therapies to Block Progression of Chronic Kidney Disease

Chronic kidney disease is a growing problem in Canada and worldwide and is associated with obesity, diabetes and vascular disease. Current therapies only treat symptoms of CKD and have no impact on inflammatory and fibrotic process that underlie the progression of the disease toward hemodialysis, kidney transplantation, or death.

KINARM Standard Tests’ Task Scores: towards a validated and effective tool for communicating to clinical communities KINARM measures of brain function

KINARM Labs™ provide robust and objective measures of brain function and dysfunction by the precise measurement of human behavior with robotics. Created by neuroscientists, KINARM Labs allow clinician-scientists to detect and quantify the sensory, motor and cognitive impact of a diverse range neurological impairments caused by stroke, cardiac arrest, TIA, mTBI, concussion, MS or Parkinson’s - all in a short

Development of dual antibody therapies for cancer

Cancer is a devastating disease defined by genetic changes that result in the activation of proteins that encourage cell growth or prevent cell death. Modern oncology aims to specifically target these tumour-promoting proteins, which has the secondary benefit of leaving normal cells unharmed, unlike chemotherapy. Recently, a number of drugs that specifically block tumour-promoting proteins have been produced, yet the results are underwhelming: most targeted therapies show an initial benefit, followed by the development of resistance.

Characterizing fucoidan-degrading enzymes from marine bacterium

Fucoidan is a polysaccharide found in brown algae (seaweed). ARC Medical Devices Inc. markets fucoidan purified from brown algae for post-surgical veterinary use to reduce interorgan adhesion development. This product works very effectively, prompting a desire to develop a similar product for use in humans. The challenge to this, however, is that fucoidan is an extremely large molecule of heterogeneous composition, making it difficult to meet the higher standards of purity and homogeneity required of medical materials for use in human subjects.

Development of Cell-Based Functional Assays to Accelerate Commercialization and Therapeutic Application of Recombinant Antibodies

Antibodies are the fastest growing segment of the pharmaceutical market, and with modern engineering technologies antibodies can be programmed to target devastating diseases. Within the immune system, antibodies fight invading bacteria and viruses. High-quality synthetic antibodies directed to disease-related targets have immense therapeutic potential. Development of cell-based assays to enable rapid identification of functionally active antibodies is a critical step in the commercialization process.